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ABSTRACT
The aims of these recommendations were to develop clinical guidelines for evaluation and mana-
gement of patients with differentiated thyroid cancer applicable to Latin American countries. The 
panel was composed by 13 members of the Latin American Thyroid Society (LATS) involved with 
research and management of thyroid cancer from different medical centers in Latin America. The 
recommendations were produced on the basis of the expert opinion of the panel with use of prin-
ciples of Evidence-Based Medicine. Following a group meeting, a first draft based on evidences 
and the expert opinions of the panel was elaborated and, later, circulated among panel members, 
for further revision. After, this document was submitted to the LATS members, for commentaries 
and considerations, and, finally, revised and refined by the authors. The final recommendations 
presented in this paper represent the state of the art on management of differentiated thyroid 
cancer applied to all Latin American countries. Arq Bras Endocrinol Metab. 2009;53(7):884-97.
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RESUMO
Estas recomendações tiveram por objetivo o desenvolvimento de diretrizes para avaliação 
e manejo de pacientes com câncer diferenciado da tiroide em países latino-americanos. Um 
painel composto por 13 membros da Sociedade Latino-Americana de Tireoide (SLAT) – que 
estavam envolvidos em pesquisas, e eram peritos no cuidado do paciente com câncer da tiroi-
de e provenientes de diferentes centros médicos latino-americanos – utilizou os princípios da 
Medicina Baseada em Evidências para produzir esse consenso. Após uma primeira reunião, um 
texto inicial foi elaborado, baseado em evidências e opiniões dos especialistas do painel e, pos-
teriormente, circulado entre os membros do painel, para revisão. Após a revisão, o documento 
foi enviado aos membros da SLAT para comentários e considerações e, finalmente, revisado e 
refinado pelos autores. As recomendações finais aqui apresentadas demonstram o estado da 
arte no manejo do câncer diferenciado da tireoide aplicadas aos países latino-americanos.Arq 
Bras Endocrinol Metab. 2009;53(7):884-97. 
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InTRODUCTIOn
The risk of malignancy in a thyroid nodule varies be-tween 5% and 10% in iodine sufficient countries, 
and the amount of iodine supplemented in table salt 
influences on the morphology of the malignant tumor 
types (1).
Programs of table salt iodination in many Latin Ame-
rican countries have produced important variations in 
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LATS’ thyroid cancer recommendations
iodine intake over the past few decades, and the impact 
of these changes on the behavior of thyroid nodules 
and cancer is still largely unknown (2). The populariza-
tion of ultrasonography (US) and the simplicity of the 
technique to serve as guidance for aspiration of nodules 
have contributed to the apparent increase in incidence 
of differentiated thyroid carcinoma, as well as modified 
the clinical presentation of the cases diagnosed in Latin 
America and all over the world (1,3). 
New imaging technologies – especially US – have 
improved the sensitivity for detection of thyroid cancer, 
which is now often found incidentally on imaging stu-
dies performed for other indications. This has led to the 
identification of many patients with microscopic papillary 
thyroid cancers – mostly of no clinical significance (4). 
New and refined surveillance approaches for pa-
tients with established diagnosis of thyroid cancer show 
that many patients who would be previously considered 
cured have, in fact, minimal residual disease. 
Differentiated thyroid carcinoma (papillary and fol-
licular) shows a wide spectrum of pathological subtypes 
according to the World Health Organization (WHO) 
system (5). Familial differentiated thyroid carcinoma 
may occur as site-specific tumors or as part of a heredi-
tary tumor syndrome (for example: familial adenoma-
tous polyposis, Cowden disease etc.). These are usually 
multicentric and occur mainly in young patients (6).
Although most patients with differentiated thyroid 
cancer have a favorable outcome, some are presenting 
with an aggressive form of the disease and a poor prog-
nosis. Physicians in care of patients with thyroid carci-
noma now have to grapple with a new array of issues 
that affect directly the decisions made in daily practice. 
A series of guidelines and consensus have been recently 
published; however, they are not always appropriate to 
different settings or countries. 
Although the Argentinean and Brazilian endocrine 
societies have already published local guidelines for the 
follow-up and treatment of differentiated thyroid can-
cer (7,8), the rest of the Latin American countries have 
not. The idea of the Latin American Thyroid Society 
(LATS) was to generate common recommendations, 
according to the different economic and social actuali-
ties of the integrating Latin American countries.
MATERIAlS AnD METhODS
A set of recommendations for evaluation and manage-
ment of patients with differentiated thyroid cancer has 
been developed by 13 members of the LATS. This pa-
nel was composed by individuals involved in research 
and management of thyroid nodules and cancer from 
distinct reference medical centers in Latin America to 
reflect different practice patterns. 
A first questionnaire assessing the most important 
issues on the subject (Table 1) was firstly sent to all 
panel members. The first meeting of the taskforce was 
held on August, 24th 2007, in Buenos Aires, Argentina. 
Prior to the meeting, the panel undertook a literature 
review by searching MedLine database. The search was 
classified by relevance according to:
1. randomized trials;
2. meta analysis;
3. clinical case series.
After the first meeting, a draft was developed. This 
preliminary text was analyzed by the entire panel of ex-
perts, and a draft document, based on the bibliographic 
search and expert opinion of the panel’s participants, as 
well as on previously published information, was elabo-
rated and circulated among panel members for further 
revision. This document was subsequently sent to some 
LATS members, for comments and discussion.
A second meeting was held in Rio de Janeiro, Bra-
zil, on December 7th 2007. The text was finally revi-
sed and refined in complete agreement by the 13 panel 
members. 
The final text aimed to represent the state of the art 
on thyroid cancer management applied to Latin Ame-
rican countries. 
RESUlTS
Preoperative staging
A series of studies with large cohorts of patients have 
demonstrated that age is a significant prognostic deter-
minant in differentiated thyroid cancer (9). Other im-
portant factors included in most prognostic classifica-
tions are gender, tumor size on US evaluation, cytology 
(aggressive variants of papillary carcinoma), and eviden-
ce of extra-thyroidal invasion (10). These factors should 
be taken into consideration in planning for surgery.
US
Before surgery, the lobe contralateral to the tumor and 
the cervical area should be carefully evaluated by US in 
search of contralateral disease and suspicious lymph no-
des at levels II, III, IV, V, and VI. It is noteworthy that 
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5. TSH-suppressive therapy
 What is the appropriate degree of TSH suppression?
 How long is TSH suppressive therapy mandatory? 
 When the suppression therapy must be avoided?
6. Follow-up protocol soon after initial therapy (surgery and radioiodine 
ablation)
•	 TSH-suppressive therapy. What is the appropriate degree of TSH 
suppression?
•	 When and what are laboratory tests indicated?
– TSH-stimulated serum thyroglobulin (levothyroxine withdrawal or 
rhTSH stimulation) and TgAb
– TSH-suppressed  serum thyroglobulin and TgAb
– Management of thyroglobulin positive and imaging modalities 
negative patients
•	 When and what are imaging modalities indicated?
– Cervical ultrasonography 
– Whole-body radioiodine scan
– Bone scintigraphy
– Computed tomography
– Magnetic resonance imaging
– FDG-PET
7. Long-term follow-up protocol
•	 TSH-suppressive therapy. What is the appropriate degree of TSH 
suppression?
•	 When and what are laboratory tests indicated?
– TSH-stimulated serum thyroglobulin (levothyroxine withdrawal or 
rhTSH stimulation) and TgAb
– TSH-suppressed  serum thyroglobulin and TgAb
•	 When and what are imaging modalities indicated?
– Cervical ultrasonography 
– Whole-body radioiodine scan
– Bone scintigraphy
– Computed tomography
– Magnetic resonance imaging
– FDG-PET
8. Flowchart or algorithm for long-term follow-up after initial treatment (surgery 
and radioiodine ablation)
9. Management of patients with recurrent or metastatic disease
•	 What is the most appropriate management of patients with local and 
regional recurrence? 
– Surgery
– 131I therapy
– Percutaneous ethanol injection
– Follow-up
•	 What is the most appropriate management of patients with distant metastases?
– Lung metastases
– Bone metastases
– Brain metastases
•	 Use of lithium in 131I therapy
•	 What is the role of external beam radiotherapy?
•	 What is the role of chemotherapy?
LATS’ thyroid cancer recommendations
1. Preoperative staging
 What are the imaging modalities and laboratory tests indicated in patients 
with thyroid cancer in preoperative staging?
•	 Ultrasonography 
•	 Color Doppler
•	 Scintigraphy
•	 Magnetic resonance imaging
•	 Computed tomography
•	 FDG-PET
•	 Laryngo-tracheoscopy
•	 Esophageal endoscopy 
•	 Suspicious lymph nodes: ultrasonography guided FNAB with the 
measurement of Tg in the washout of the needle
•	 Serum thyroglobulin /TgAb
•	 Calcitonin
•	 Others
2. Surgical treatment
 What is the appropriate primary surgical treatment of patients with thyroid 
cancer?
 a) Surgical options for indeterminate cytology
•	 Thyroid lobectomy (and isthmectomy?)
•	 Completion thyroidectomy after lobectomy?
•	 Near-total or total thyroidectomy
 b) Surgical options for malignant cytology (low-risk and high-risk patients)
•	 Thyroid lobectomy (and isthmectomy?)
•	 Completion thyroidectomy after lobectomy?
•	 Near-total or total thyroidectomy
 c) Lymph nodes dissection
•	 Central compartment (Level VI) neck dissection
•	 Lateral compartment (Level II-IV) neck dissection. Affected side/both 
sides 
•	 Posterior triangle (Level V) neck dissection
 d) Surgical complications
•	 Laryngeal nerve palsy (laryngoscopy?)
•	 Hypocalcemia (Ionized calcium/PTH?)
3. Postoperative staging
 Which should be the postoperative systems used?
4. Postoperative radiodine administration
 When is the postoperative radiodine administration indicated?
 Should urinary iodine excretion be measured before the radioiodine 
administration?
 Is a low iodine diet necessary before remnant ablation?
 Should pretreatment diagnostic scan be performed before remnant ablation?
 Is there a reduction in uptake of the 131I therapy dose induced by a 
pretreatment diagnostic dose?
 What is the accuracy of low-dose 131I scan and post-treatment whole-body scan?
 What should be the activity of 131I used for remnant ablation after thyroxine 
withdrawal or recombinant human TSH stimulation?  
 Can rhTSH be used for remnant ablation in your country?
 Should Tg be measured before the radiodiodine administration?
 Is a post-therapy scan necessary after remnant ablation?
Table 1. Questions pertaining differentiated thyroid cancer treatment and follow-up sent to the 13 panel members
the size of the tumor may be underestimated when me-
asured by US evaluation. This is particularly important 
in nodules measuring less than 1 cm, in which partial 
thyroidectomy might be considered (9). Routine use of 
other imaging techniques, such as computed tomogra-
phy (CT), magnetic resonance (MRI), positron emis-
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sion tomography (PET) scan are not recommended 
before surgery, but may be useful in selected patients 
with aggressive cancers presenting with local extension 
or distant metastases.
laboratory tests
Routine measurement of serum Tg levels before sur-
gery is not recommended. Many studies have sugges-
ted the determination of preoperative serum calcitonin 
levels for detection of medullary thyroid cancer, but the 
cost-effectiveness of this approach is still unclear (11). 
Preoperative calcitonin may be measured when follicu-
lar cell or Hürthle cell neoplasia is suspected on FNAB, 
since medullary carcinoma with oncocytic features and 
with neoplastic follicular cell component may present 
that way (11). 
The panel recommends the ultrasonographic neck 
evaluation previous to surgery but oppose to the mea-
surement of thyroglobulin as a prognostic or diagnostic 
study before surgery.
Surgical treatment 
The panel discussed very carefully this topic: a less ag-
gressive surgical treatment (such as lobectomy plus isth-
mectomy, for example) is proposed by some, for low-risk 
patients with the argument that this approach may help 
preserve thyroid function and spare some patients from 
lifelong thyroid hormone replacement. However, L-T4 
therapy is required in 50% of the patients immediately 
after lobectomy (12). In a majority of these patients, 
L-T4 is ultimately required lifelong. Also, recurrence 
rates for patients with papillary carcinoma treated with 
lobectomy plus isthmectomy are higher than for tho-
se undergoing total thyroidectomy according to some 
(13) – but not all (14) – studies. There are a surprisingly 
high number of patients with papillary microcarcinomas 
(≤ 1 cm) with bilateral or multifocal disease, indicating 
that, even when these tumors are small in size, there is 
risk of leaving behind residual tumor in the contralate-
ral lobe after hemithyroidectomy. Besides, performing 
total thyroidectomy at the time of diagnosis prevents 
the need for an additional surgical procedure in case of 
contralateral disease developed in the future. Patients 
with small (< 2 cm) single nodules located far from the 
gland capsule and with no signs of extension are consi-
dered low risk for progression and, sometimes, referred 
for partial thyroidectomy. However, the prevalence of 
recurrence in these patients is not negligible (15,16). 
Taking into consideration the current lack of relia-
ble markers of tumor progression and the fact that pa-
pillary microcarcinomas may occasionally be multifocal, 
invade the thyroid capsule, or present with lymph node 
or distant metastases (16), the panel recommends total 
thyroidectomy for differentiated thyroid carcinomas in-
dependent of size. 
Although some patients may be over-treated by this 
approach, the panel considers that total thyroidectomy 
allows an adequate follow-up by permitting reliable Tg 
measurements. 
There is an increased risk of hypoparathyroidism 
and recurrent laryngeal nerve injury following total 
thyroidectomy. In specialized centers, however, the oc-
currence of these complications is low and reported to 
be around 6% for hypoparathyroidism (usually manifes-
ting with transient hypocalcemia) and less than 1% for 
recurrent laryngeal injury. 
Patients with indeterminate cytology on FNAB 
should be followed up and surgery should be indica-
ted only in patients with risk factors (neck irradiation, 
familial papillary thyroid cancer) or in case of nodule 
enlargement. In these situations, lobectomy plus isth-
mectom is recommended, whereas total thyroidectomy 
is indicated for those with suspicious or malignant 
thyroid carcinoma.
There may be some situations when total thyroidec-
tomy might not be performed, due to the low adheren-
ce of the patient to the follow-up. These circumstances 
are very characteristics of some specific regions of Latin 
America and they could happen in patients who live far 
away from the hospital and who are probably supposed 
not to return for the follow-up. In situations like this, 
that are usually seen in the inner cities of some Latin 
American countries, it could be preferable to perform 
a lobectomy, considering that some of these patients 
are probably not taking levothyroxine and the quality 
of life might be seriously affected with the chronic hy-
pothyroid state. 
If a unifocal microcarcinoma (in a very low-risk pa-
tient, for example) is diagnosed after a lobectomy made 
due to a diagnosis of a benign thyroid disorder, the 
completion thyroidectomy may be avoided. 
Regarding surgical treatment, the panel recommen-
ds total thyroidectomy when a prospective diagnosis of 
thyroid cancer is performed, whatever the tumor size 
is. Lobectomy might be an option when a retrospecti-
ve diagnosis of a microcarcinoma is made or when the 
cultural characteristic of the diagnosed patient might 
LATS’ thyroid cancer recommendations
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interfere with the subsequent controls in the long-term 
follow-up.
Selective neck dissection for thyroid cancer
The procedure of choice for thyroid cancer is selective 
neck dissection (SND), most often indicated with or 
without dissection of other neck levels. This procedure 
refers to the removal of lymph nodes within the central 
compartment of the neck, including the paratracheal, 
precricoid (Delphian), and perithyroidal lymph nodes, 
as well as the nodes located along the recurrent laryn-
geal nerves. This procedure is also known as the ante-
rior neck dissection or the central compartment neck 
dissection. In the presence of metastases extending be-
low the level of the suprasternal notch, dissection of 
the superior mediastinal nodes may be indicated; in this 
case, the procedure is designated SND (level VII, supe-
rior mediastinal nodes). In case of thyroid cancer with 
evidence of lateral nodal metastases, the procedure of 
choice should include the jugular nodes as well as the 
posterior triangle nodes and would be designated SND 
(II-V, VI) (7).
Central compartment neck dissection should be 
routinely considered only for those patients with T3 or 
T4 (TNM status) and is not warranted in all patients. 
However, routine evaluation of the paratracheal 
area is recommended during surgery, in order to check 
for any evidence of suspicious lymph nodes. If suspicion 
is raised about a paratracheal area lymph node, a frozen 
section may be obtained and appropriate paratracheal 
clearance is recommended based on the pathological 
finding. Paratracheal clearance should include removal 
of levels VI and VII lymph nodes, if clinically apparent. 
Level VI lymph nodes include paratracheal nodes, whi-
le level VII includes superior mediastinal nodes, which 
are more concerning in patients with obvious metas-
tatic disease at level VI. If at the time of surgery the-
re is obvious metastatic disease in the jugular chain or 
lateral neck, modified neck dissection with removal of 
the lymph nodes at levels II, III, IV, and V is generally 
recommended. Modified neck dissection for thyroid 
carcinoma preserves all the important structures, such 
as the sternomastoid muscle, internal jugular vein, and 
accessory nerve, along with the submandibular salivary 
gland (17,18).
Even though modified neck dissection is a reliable 
and safe surgical procedure for metastatic thyroid car-
cinoma, consideration must be given to certain com-
plications, including high incidence of temporary and 
permanent hypoparathyroidism, recurrent larynge-
al nerve injury, accessory nerve weakness leading to 
shoulder disability, chyle leak, bleeding and hematoma, 
Horner’s syndrome, and injury to the brachial plexus 
or hypoglossal nerve (18). The consideration for neck 
dissection is evidently based on the surgeon experience 
in this procedure.
Patients undergoing neck dissection should be ob-
served carefully in the postoperative period for serum 
calcium levels and symptoms of hypocalcemia, such as 
carpopedal spasm or tetany. These patients should be 
treated and maintained on calcium and vitamin D su-
pplementation until serum calcium returns to normal 
levels, which may take up to two to three months. 
At the time of surgery, if any portion of the para-
thyroid gland is identified as devascularized, parathyroid 
autotransplantation should be performed, preferably in 
the sternomastoid muscle or in the strap muscles. Prior 
to autotransplantation, it is important to reserve a small 
piece for frozen section analysis to confirm that the au-
totransplanted tissue is, in fact, a parathyroid gland, and 
not a lymph node or metastatic thyroid carcinoma. 
SND is indicated in patients with diagnosed metas-
tatic lymph nodes. The panel does not recommend the 
routine central neck dissection in all patients with diag-
nosis of papillary thyroid cancer; however, it is deserved 
for any patient with a T3 or T4 (TNM status).
Postoperative staging
The American Joint Committee on Cancer/Internatio-
nal Union against Cancer (AJCC/UICC) TNM sta-
ging system (6th edition) should be used for assessment 
of patients with differentiated thyroid cancer on diag-
nosis and on every follow-up visit. 
Risk stratification
The TNM system allows good stratification of the risk 
of death, but is weak in the prognostication of the re-
currence risk (19). However, the following classifica-
tion takes into consideration other variables that allow 
a reliable evaluation of the risk of disease persistence/
recurrence. 
Clinical and pathological risk stratification following 
initial treatment might be included in the following ca-
tegories: 
•	 very	low	risk:	patients	with	unifocal	microcarci-
noma and no extension beyond the thyroid cap-
sule (T1 ≤ 1 cm) and no local or distant metasta-
ses N0M0; 
LATS’ thyroid cancer recommendations
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•	 low	risk:	patients	with	uni-	or	multifocal	tumors	
(T1 > 1 cm, multifocal T1 or T2), no local or 
distant metastases (N0M0), in which all macros-
copic tumor has been eliminated, no tumor inva-
sion of locoregional tissues or structures, no vas-
cular invasion, no 131I uptake outside the thyroid 
bed on the first post-treatment whole body 
scanning (WBS) scan, and with non-aggressive 
histological features such as tall cell, insular and 
columnar cell carcinomas;
•	 high	 risk:	patients	>	45	years	of	 age	with	 large	
tumors (T3 and T4) or any T with lymph node/
regional metastases (N1), residual cancer after 
surgery (neck, distant sites, or both) or persis-
tent disease, tumor extension beyond the thyroid 
capsule, distant metastases (M1) in any age, or 
aggressive tumor histology (for example, tall cell, 
columnar cell or insular types). 
Postoperative radioiodine administration
Effective thyroid ablation with radioiodine requires 
adequate stimulation by TSH. Remnant ablation can 
be achieved with the same effectiveness either by ad-
ministration of recombinant human TSH or by thyroid 
hormone withdrawal. Radioablation is performed after 
thyroidectomy to destroy normal thyroid tissue that 
may have been left behind and increase the sensibility 
and specificity of Tg measurement. Many studies have 
shown that patients who undergo post-surgical radio-
ablation of thyroid remnants have decreased disease 
recurrence rates compared with those who do not re-
ceive ablation (20,21). Others, however, have conclu-
ded that, in low-risk patients, the incremental benefit of 
remnant ablation is unclear (22). Patients with papillary 
microcarcinoma receive ablation, especially when mul-
ticentricity, lymph node metastases and vascular or cap-
sular invasion are encountered (23).
The panel recommends radioablation of thyroid 
remnants in all patients with high-risk thyroid cancer 
following total thyroidectomy. The procedure could be 
performed in low-risk patients and it is not mandatory 
in patients categorized as very low risk. 
A low-iodine diet should be instituted 15 days be-
fore 131I therapy and continued for two days after that. 
A daily iodine intake of about 50 µg increases thyroidal 
131I uptake and can potentially double the radiation per 
100 mCi of 131I administered. The diet can be rather 
tedious, but an iodine intake limited to 50 µg a day can 
be achieved by restricting use of iodized salt, dairy pro-
ducts, eggs, and seafood (24). Although not routinely 
required, measurement of urinary iodine excretion may 
be useful in identifying patients in whom radioiodine 
should not be administered due to persistently high 
body iodine levels. 
A diagnostic scan before radioiodine thyroid abla-
tion is not usually indicated, but might be considered 
on special circumstances. For example, for assessment 
of the extent of the thyroidectomy in which large 
thyroid remnants may have remained and further sur-
gery is required. It has been shown that diagnostic ra-
dioiodine doses may induce thyroid “stunning”. This 
occurs most prominently with higher doses (> 3 mCi) 
of 131I (25,26) and with increasing time between the 
diagnostic and the therapeutic 131I administration (26). 
Stunning is usually not visually appreciated with 123I or 
131I doses below 3 mCi.
The usefulness of a pre-ablation radioiodine whole 
body scan is controversial. 
Some of the members of the panel consider that a 
radioiodine dose around 100 µCi 131I could be admi-
nistered only to perform a thyroid scintigraphy to show 
the extent of the surgery in selected cases, while others 
accept radioiodine doses up to 3 mCi 131I to make a 
whole body scan before ablation.
Radioablation of thyroid remnants after thyroid 
hormone withdrawal can be accomplished in most 
instances by a single 131I dose of 30 mCi, which deli-
vers to the patient about 10 whole body rads (27,28). 
A dose of 100 mCi 131I is more certain to provide abla-
tion with a single administration than smaller doses, at 
the expense, however, of higher radiation exposure to 
the patient (29,30). 
Radioiodine doses in the range of 90 to 100 mCi 131I 
are recommended when rhTSH is administered as an ad-
juvant before ablation (31,32). However, recent publi-
cations have shown that 50 mCi 131I is equally effective 
to 100 mCi 131I for thyroid remnant ablation following 
rhTSH, with no interruption in L-T4 administration 
(33,34). The use of rhTSH for ablation has shown to 
produce lesser exposure of radioiodine to the bone mar-
row and lowered toxicity related to the radioiodine dose 
than when administered after withdrawal (35,36). Short 
term recurrence of disease seems to be the same when 
a patient is prepared after thyroid hormone withdrawal 
than when performed after rhTSH (32).
In Latin America, the use of rhTSH has been approved 
as an adjuvant for thyroid remnant ablation in Argentina, 
Brazil, Chile, Colombia, Mexico, Peru and Uruguay.
LATS’ thyroid cancer recommendations
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A post-therapeutic (WB) should be performed 
within five to eight days after radioiodine ablation of 
thyroid remnants to detect additional uptaking foci, 
that may not have been detected with the diagnostic 
radioiodine dose (37). 
The panel recommends the use of radioiodine doses 
higher than 30 mCi 131I when performed after withdrawal. 
If rhTSH is used, a radioiodine dose higher than 50 mCi 
131I seems to be enough to destroy the thyroid remnants.
TSh-suppressive therapy
TSH-suppressive therapy is associated with increased 
survival (38). 
In patients with low-risk thyroid cancer and without 
evidence of recurrence or metastases, serum TSH levels 
may be maintained between 0.4 and 1.0 mU/L. Pa-
tients with high risk should receive TSH suppression 
while they keep the high-risk status; aimed serum TSH 
values in these patients should be below 0.1 mU/L. If a 
high-risk patient is defined as free of disease, a decrease 
in L-T4 dose is recommended after three to five years of 
follow-up. In very low-risk patients, it is not necessary 
to suppress TSH levels. The thyroid hormone therapy 
can be administered in order to keep a TSH level into 
the normal range.
Contraindications for suppressive therapy are: atrial 
fibrillation, severe osteoporosis, and ischemic cardio-
vascular disease (39). 
Immediate follow-up after surgery and radioiodine 
ablation
The first serum stimulated Tg determination after hy-
pothyroidism post-surgery is a good prognosticator. An 
initial Tg value above 70 ng/mL has a positive pre-
dictive value of 90% for detection of metastases (40). 
Pre-ablative Tg levels have also been shown to be an in-
dependent prognostic indicator for disease-free remis-
sion by another study, in which levels above 27.5 ng/
mL were associated with a positive predictive value of 
98% (41). The ideal timing for serum Tg measurement 
is immediately before 131I administration, if patients 
undergo L-T4 withdrawal. The Tg measurement after 
rhTSH may not reflect only the thyroid cells stimula-
tion, but also the thyroid cellular destruction, conside-
ring that it must be measured after the radioiodine dose 
administration (fifth day after the first injection). 
Serum Tg should be measured with a sensitive im-
munometric assay (functional sensitivity < 1.0 ng/mL) 
standardized on the European reference standard (CRM 
457). The emergence of new second generation Tg assays 
or molecular markers in the future might allow a more 
adequate follow-up of patients with residual thyroid tissue. 
The presence of circulating thyroglobulin antibodies 
(Tg-Ab) may interfere with immunometric assays and 
yield falsely lower Tg determinations. Approximately 
25% of the thyroid cancer patients and 10% of the ge-
neral population have Tg-Ab, and their presence must 
be ruled out by direct measurement of Tg-Ab, instead 
of using the Tg recovery test. Serial serum Tg-Ab me-
asurements may serve as an imprecise surrogate marker 
of residual normal thyroid tissue or tumor (42).
The panel recommends the assessment of serum Tg 
before ablation when it will be performed after thyroid 
hormone withdrawal. The moment when measuring 
serum Tg after ablation with rhTSH has not been 
addressed yet.
TSh-stimulated serum thyroglobulin and Tg-Ab 
measurement in short term follow-up
In very low-risk and non-ablated patients, the risk of 
persistent or recurrent disease is small by definition, 
and TSH-stimulated serum Tg and Tg-Ab measure-
ment is usually not necessary. Follow-up with serum 
Tg and Tg-Ab determinations during L-T4 treatment 
combined with neck US every 6 to 12 months is re-
commended for these patients.
In patients with low-risk thyroid carcinoma, serum 
Tg and Tg-Ab measurement following L-T4 withdrawal 
or rhTSH administration should be performed around 
12 months after surgery. At this point, WBS is not man-
datory (43,44) (Figure 1).
A Tg cut-off level of 2 ng/mL after rhTSH stimu-
lation is highly sensitive to identify patients with persis-
tent tumor (45). Approximately 20% of patients who are 
clinically free of disease and have serum Tg levels below 
1 ng/mL during L-T4 suppressive therapy will present 
levels above 2 ng/mL after rhTSH or thyroid hormo-
ne withdrawal (46); persistent tumor may be identified 
on imaging studies in about 1/3 of these patients. In 
patients with small cervical lymph node metastases or 
less differentiated tumors, serum non-stimulated Tg 
measurements have lower sensitivity (47). The clinical 
significance of minimally detectable Tg levels is still un-
clear, especially when an increase is only detected after 
TSH stimulation. In any case, a rising (non-stimulated 
or stimulated) serum Tg may indicate a disease likely to 
become clinically apparent (46,47).
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Total thyroidectomy
(TT)
Withdrawal
4 weeks after TT
5th week: 
remnant ablation with 131I
After pathology confirmation
Remnant ablation with 131I 
(> 50 mCi)
5-7 days after 131I treatment:
post-dose WBS
Low-risk patient:
measurement of stimulated Tg
(withdrawal/rhTSH)
High-risk patient:
diagnostic WBS/stimulated 
Tg/131I treatment
Diagnostic WBS/stimulated Tg
131I treatment
Surgery
Diagnostic WBS/
131I treatment
Negative uptake
Decreasing Tg/Tg-Ab (-)Undetectable Tg/Tg-Ab
Control Tg/TgAb 
under L-T4 therapy 
plus US every 12 
months
Control Tg/TgAb
 under L-T4 therapy every 6 to 
12 months
Image modalities (CT, MRI, 
FDG-PET, 131I treatment?)
Image modalities (CT, MRI, 
FDG-PET, 131I treatment?)
Negative uptake   
Increasing Tg/Tg-Ab Detectable Tg
6 to 12 months  
after surgery
L-T4 withdrawal during  
3-4 weeks/rhTSH + measurement  
of Tg/Tg-Ab
Neck US negative
Undetectable Tg and Tg-Ab
Neck US negative
Detectable Tg levels
Neck US positive
FNAB positive
6 to 12 months (under thyroid hormone suppressive therapy) 
 neck US + Tg/Tg Ab assessment
rhTSH
Figure 1. Suggested approach in patients with differentiated thyroid carcinoma.
It is noteworthy that results of serum Tg measure-
ments performed on the same serum specimen differ 
among laboratories. Therefore, the Tg cut-off may di-
ffer slightly among medical centers and different labo-
ratories. The frequency for subsequent stimulated tes-
ting is not clearly established for patients found to be 
free from the disease (47). 
In patients with low-risk thyroid cancer, the panel 
recommends to measure a stimulated Tg level after one 
year of initial treatment. Diagnostic WBS is not neces-
sary, at this point, in this group of patients.
Serum thyroglobulin and Tg-Ab measurement during 
l-T4 therapy
Measurement of serum Tg and Tg-Ab during TSH su-
ppressive therapy should be performed between 6 to 12 
months after surgery, based on each patient’s risk. 
Cervical US 
Cervical US is highly sensitive in detecting cervical me-
tastases in patients with differentiated thyroid cancer, 
especially when associated to a stimulated Tg level (48). 
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It should be ideally performed at 6 and 12 months af-
ter surgery, and annually thereafter, depending on the 
patient’s risk for recurrence and on Tg levels.
Neck US is an operator-dependent procedure, and 
a learning curve may improve individual performance. 
This procedure is more sensitive than neck palpation, 
has the ability to detect lymph nodes as small as 2 to 
3 mm in diameter, and may be used routinely for asses-
sing lymph node chains as well as evaluating the thyroid 
bed. Benign lymph node hyperplasia is frequent and 
a distinction should be made between hyperplasia and 
metastatic disease. Important US criteria suggesting 
malignancy include cystic appearance, hyperechoic 
punctuations (microcalcifications), loss of hyperechoic 
hilum and peripheral vascularization (49). 
For lymph nodes that present a short axis larger 
than 0.5 cm that persist over several months, the spe-
cificity of neck US may be improved by assessing the 
US characteristics of the lymph nodes and by perfor-
ming US-FNAB for cytology and Tg measurement in 
the aspirate fluid. Lymph nodes with short axis equal or 
smaller than 0.5 cm should be carefully described and 
followed with periodical US monitoring.
US should be performed initially at 3 to 6 months 
after total thyroidectomy and, then, every 6 to 12 mon-
ths, depending on the patient risk. If one low-risk or 
very low-risk patient is considered free from the disease 
after three to five years of follow-up, then, no more 
annual ultrasonographic control is needed. 
Indications for other imaging modalities
WBS
An increase in TSH levels should be obtained before 
administration of 131I for diagnosis or therapeutic pur-
pose. High TSH levels can be achieved after three to 
four weeks of thyroid hormone withdrawal. A TSH level 
higher than 30 mUI/mL is usually required (50,51). 
Another option is the administration of rhTSH (0.9 mg 
intramuscularly) for two consecutive days, followed by 
131I on the third day. Serum Tg should be measured 
on the fifth day, when performed after rhTSH admi-
nistration, and before radioiodine administration, when 
performed after withdrawal (43,45,52). 
Following administration of 131I for ablation or thera-
py, WBS should be performed within five to seven days.
A practical approach for the follow-up of patients 
with differentiated thyroid cancer can be appreciated 
in figure 1.
Bone scintigraphy
The panel does not recommend routine bone scinti-
graphy.
Computed tomography
Recommendations for CT include suspicion of lung, 
mediastinal, CNS and bone metastases.
Magnetic resonance imaging
MRI is useful in the diagnosis of mediastinal and cen-
tral nervous system metastases.
FDG-PET
FDG-PET is recommended for patients with detecta-
ble non-stimulated or stimulated serum Tg levels (abo-
ve 10 ng/mL), but negative WBS, to help identifying 
metastatic lesions (53). Stimulation with endogenous 
TSH after L-T4 withdrawal or rhTSH (54) and CT fu-
sion may enhance the sensitivity and specificity of FDG-
PET scanning.
Management of patients with elevated Tg and 
negative imaging tests 
Pulmonary metastases may occasionally be discovered 
on post-treatment WBS after administration of a lar-
ge 131I dose (55). In one study, about 6% of 283 pa-
tients with high serum Tg levels treated with 100 mCi 
131I had distant metastases detected on post-treatment 
WBS that were not detected on a 2 mCi pre-treatment 
scan (56). 
The panel suggests that patients with negative ima-
ging and increasing non-stimulated or stimulated Tg 
levels, higher than 10 ng/mL, might be treated with 
a higher radioiodine dose (> 100 mCi 131I) to increase 
radioiodine uptake of eventual metastases. If no uptake 
is visible after high radioiodine dose, no additional ra-
dioiodine should be administered.
low functional sensitivity Tg assays
Low functional sensitivity Tg assays have a higher sensi-
tivity, but at the expense of a lower specificity (57,58). 
The future emergence of second generation Tg assays 
will probably reduce the need of TSH-stimulated Tg 
measurement in some patients (59).
The panel does not recommend the routine use of 
low functional sensitivity Tg assays until more evidence 
is published regarding its efficacy.
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Management of patients with positive Tg-Ab
In patients with Tg-Ab positivity, undetectable serum 
Tg levels should not be interpreted as evidence of re-
mission. These patients must be monitored with perio-
dical neck US and diagnostic 131I WBS instead of se-
rum Tg determinations. If there is suspicion of distant 
disease, patients should also undergo evaluation with 
other imaging techniques such as CT, MRI, or FDG-
PET. The disappearance of Tg-Ab during follow-up 
may itself be considered evidence of remission in these 
patients.
Management of patients with recurrent or metastatic 
disease
Surgery
When local recurrences are detected, a complete ipsila-
teral dissection of the compartments with persistent/
recurrent disease should be performed, sparing vital 
structures whenever possible (for example, modified 
levels II-V neck dissection sparing the spinal accessory 
nerve, the internal jugular vein, and the sternocleido-
mastoid muscle). Neck dissection of the VI and VII 
compartments should be carried out in case it was not 
performed during total thyroidectomy.
131I therapy
Administration of fixed doses of 131I to patients with 
metastatic disease is a simpler, but sometimes not safer, 
approach compared with administration of calculated 
doses. The main disadvantage of fixed doses, however, 
is that some patients may receive insufficient 131I to ade-
quately treat their tumors. However, the disadvantage 
with high fixed doses, especially in elderly people, can 
be the risk of exceeding the maximum tolerated radia-
tion dose.
In general, lymph node metastases too small to be 
excised surgically should be treated with doses ranging 
from 150 to 175 mCi. Patients with cancer growth 
through the thyroid capsule should be managed with 
doses ranging from 150 to 200 mCi, and those with 
distant metastases with 200 to 300 mCi, which is unli-
kely to cause severe radiation sickness or serious dama-
ge to critical structures. Lung metastases are generally 
treated with doses between 200 to 250 mCi 131I. Again, 
this radioiodine doses can be deleterious, above all in 
the elderly. Caution is recommended when radioiodine 
doses are empirically administered in older patients.
131I treatment of metastases after rhTSh 
The panel recommends that thyroid hormone withdra-
wal precede the treatment of metastases with 131I. Ho-
wever, in elderly patients or in those with contraindi-
cation for thyroid hormone withdrawal, good results 
have been shown with 131I therapy preceded by rhTSH 
stimulation (60,61). The use of prophylactic glucocor-
ticoids is recommended when therapeutic 131I is admi-
nistered in patients with metastatic disease after rhTSH 
to prevent tumor enlargement (61,62).
The ideal approach for patients with metastatic le-
sions is real dosimetry. Recent studies using PET scans 
(with 124I) have shown that this approach allows cal-
culation of both the volume of the metastatic lesions 
and the radioiodine uptake (63). Therapeutic options 
for patients with locally advanced disease not able to 
receive surgical treatment and/or distant metastases are 
rarely curative, but may be effective in reducing tumor 
size and improving quality of life.
Follow-up in patients with metastatic disease
In patients who develop metastatic disease that uptakes 
131I, new doses of 131I should be administered until di-
sease control, appearance of adverse events, or loss of 
radioiodine uptake.
lung metastases
In case a single nodular metastasis is present in the 
lung, surgical excision is recommended, provided there 
is easy access. If multinodular or diffuse metastases are 
encountered, radioiodine should be the treatment of 
choice.
Bone metastases 
Bone metastases should be treated with a combination 
of surgery when possible, administration of 131I, if up-
take is present, and external beam radiotherapy either 
as a palliative treatment or to help control pain. 
Brain metastases
Depending on the accessibility, surgery is recommen-
ded in this case, followed by radioiodine administra-
tion. Special care should be taken with occurrence of 
hemorrhagic stroke after radioiodine; in this case, glu-
cocorticoids should be used preventively. If the tumor 
is unresectable and non-iodine avid, external beam ra-
diotherapy should be considered to provide palliation. 
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Glucocorticoids is recommended when therapeutic 131I 
is administered in patients with metastatic brain disease 
to prevent tumor enlargement due to swelling.
Use of lithium with 131I therapy
Lithium may be a useful adjuvant for 131I therapy of 
metastatic disease, increasing both the accumulation 
and the retention of the isotope in the lesion. Given at 
a dose of 300 mg (10 mg/kg) one to three times daily 
and starting about a week before 131I therapy, lithium 
increases uptake in metastatic lesions while only slightly 
increasing it in normal thyroid tissue. The drug enhan-
ces 131I retention probably as a result of its inhibitory 
effect on iodine release from both normal and neoplas-
tic follicular cells (64).
Lithium maximizes the irradiation of tumors in whi-
ch the biologic half-life of iodine is less than six days 
without increasing irradiation to other organs. The lar-
gest increase in tumor irradiation occurs in lesions with 
a biological half-life of less than three days. Retention 
of 131I during lithium therapy increases 50% in tumors 
and 90% in thyroid remnants, the net effect being more 
than a 2-fold average increase in the irradiation dose 
to metastatic tumor. Serum lithium levels should be 
measured daily and maintained between 0.8 and 1.2 
nmol/L. The drug may be continued for five to seven 
days after therapy, and, since lithium levels cannot be 
measured immediately after 131I therapy, one must care-
fully avoid lithium toxicity during this time (64).
The panel considers that lithium might be used in 
selected cases to increase the effect of the radiodiodine 
in selected patients with metastatic disease.
External beam radiotherapy
External beam radiotherapy should be used as palliative 
therapy or for pain control. It may be recommended as 
initial treatment for recurrent or unresectable tumors, 
or for tumors with local invasion, presumed to have 
macro- or microscopic residual disease that do not con-
centrate 131I. External beam radiotherapy may also be 
indicated in patients with bone or brain metastases. 
Other considerations
For patients with locally advanced disease, unresectable 
cancer and/or distant metastases in whom all therapeu-
tic options have failed and disease progresses, there is 
the option of systemic chemotherapy with doxorubicin 
as a single agent or combined with cisplatin (65).
In general, the response rates are low, short lasting, 
and associated with a high degree of toxicity.
Targeted therapy in advanced thyroid cancer
Targeted therapies are generally cytostatic and not 
cytotoxic, which may pose a problem, since thyroid 
cancer requires life-long therapy. This may be satisfac-
tory if the drug has low toxicity and is well tolerated. 
However, there is usually a high risk that ‘‘resting’’ 
neoplastic cells may develop compensatory pathways, 
often by acquiring other mutations leading to disease 
progression.
Gefitinib is a small molecule inhibitor of EGFR 
tyrosine kinase. Therapy with oral dose of 250 mg once 
daily achieves reduction in tumor volume. However, in 
a phase II study, it did not meet criteria for partial res-
ponse rate in 32% of the patients and stabilization of 
the disease in 46%, 24%, and 12% of the patients after 3, 
6, and 12 months of treatment, respectively (66).
Motesanib diphosphate (AMG 706) is a novel oral 
inhibitor of vascular endothelial growth factor (VEGF) 
receptors. In a phase II trial in patients with advanced 
thyroid cancer, out of 93 patients with follicular cell-
derived thyroid cancer treated with 125 mg of motesa-
nib diphosphate, 14% experienced a complete or partial 
response and 67% had stable disease (67).
Sorafenib is a kinase inhibitor, including Raf kinase, 
VEGF receptor, platelet-derived growth factor recep-
tor and RET tyrosine kinases. In a phase II trial in 30 
patients with advanced thyroid cancer, partial remission 
was achieved in 7 (23%) and stable disease in 16 (53%) 
patients (68).
Others kinase inhibitors that have been used in pha-
se II clinical trials with partial response or stable disease 
include axitinib (VEGFR) and sunitinib (RET, VEGFR 
and PDGFR) (69).
Thalidomide is an antiangiogenic agent and has 
been used for therapy of radioiodine-unresponsive and 
rapidly progressive thyroid carcinomas with partial res-
ponse in 18% and stable disease in 32% of the patients. 
Daily dose starts at 200 mg and is increased over six 
weeks to 800 mg or to the maximum tolerated dose 
(70). The kinase inhibitors and other agents that tar-
get vascularity appear to have activity in thyroid cancer 
that results in partial remission in some patients and 
stable disease in a large group of patients (approxima-
tely 50%). These agents appear unlikely to cure patients 
with progressive metastatic disease. Also, treatment-
related adverse events are common with these drugs 
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and can reduce quality of life. Potentially severe side 
effects include diarrhea, hypertension, fatigue, weight 
loss, and hand-foot syndrome.
The panel recommends considering the enrolling of 
patients with no other therapeutic option in any clinical 
trials available.
Thyroid cancer in children
It should be noted that children usually have larger 
tumors and a higher incidence of lymph node me-
tastases at presentation. According to the large series 
from the Cancer Registry of England and Wales the 
proportion of childhood thyroid cancer was: papilla-
ry carcinoma (68%), follicular carcinoma (11%), me-
dullary carcinoma (17%) and others (4%). Cervical 
lymph node involvement was present in the majority 
of children affected with thyroid cancer (71).
Most authors recommend total or near-total thyroi-
dectomy followed by ablation with 131I and thyroid 
hormone suppressive therapy in children with differen-
tiated thyroid carcinoma. When metastases are present, 
selective lymph node dissection is indicated. 
Although rhTSH is not approved to be used in this 
setting, in Latin America we had one of the first expe-
riences of its use (72).
Differentiated thyroid cancer during pregnancy
Pregnant women who are diagnosed with thyroid can-
cer share similar physical findings, pathological tumor 
features and outcome as those who were not pregnant 
(73). Treatment in this group of patients is also similar 
to that in non-pregnant women. In case of differentia-
ted thyroid cancer, the prognosis among pregnant and 
non-pregnant women of the same age is equal. The use 
of 131I for diagnostic or therapeutic purposes after deli-
very is safe, providing the patient is not breastfeeding. 
The panel recommends that the diagnosis and treat-
ment of thyroid cancer that occurs during pregnancy be 
delayed until after delivery in most patients.
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